Analysts expect West Pharmaceutical Services Inc. (NYSE:WST) to post earnings per share of $0.72 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for West Pharmaceutical Services’ earnings. The highest EPS estimate is $0.73 and the lowest is $0.71. West Pharmaceutical Services reported earnings per share of $0.67 during the same quarter last year, which suggests a positive year-over-year growth rate of 7.5%. The company is scheduled to issue its next quarterly earnings report on Thursday, October 25th.
On average, analysts expect that West Pharmaceutical Services will report full year earnings of $2.82 per share for the current fiscal year, with EPS estimates ranging from $2.80 to $2.84. For the next financial year, analysts forecast that the company will report earnings of $3.21 per share, with EPS estimates ranging from $3.06 to $3.35. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.03. The business had revenue of $447.50 million during the quarter, compared to analyst estimates of $422.57 million. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. West Pharmaceutical Services’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period last year, the company earned $0.66 EPS.
Several brokerages recently issued reports on WST. Zacks Investment Research lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. ValuEngine raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Tuesday, June 12th. Finally, Bank of America lowered West Pharmaceutical Services from a “neutral” rating to an “underperform” rating and set a $85.00 target price for the company. in a research report on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $108.33.
In other news, VP Daniel Malone sold 5,000 shares of West Pharmaceutical Services stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $97.24, for a total value of $486,200.00. Following the completion of the transaction, the vice president now directly owns 34,020 shares of the company’s stock, valued at approximately $3,308,104.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO William J. Federici sold 42,869 shares of West Pharmaceutical Services stock in a transaction dated Friday, June 8th. The stock was sold at an average price of $96.09, for a total value of $4,119,282.21. Following the completion of the transaction, the chief financial officer now directly owns 270,681 shares of the company’s stock, valued at $26,009,737.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,327 shares of company stock valued at $6,983,316. 2.70% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the company. Integrated Investment Consultants LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $155,000. Toronto Dominion Bank raised its position in shares of West Pharmaceutical Services by 815.7% in the 1st quarter. Toronto Dominion Bank now owns 1,923 shares of the medical instruments supplier’s stock worth $170,000 after acquiring an additional 1,713 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of West Pharmaceutical Services by 53.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 1,994 shares of the medical instruments supplier’s stock worth $176,000 after acquiring an additional 691 shares in the last quarter. First Allied Advisory Services Inc. bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $200,000. Finally, Alps Advisors Inc. bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $206,000. 96.01% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:WST opened at $116.02 on Wednesday. The firm has a market cap of $8.44 billion, a P/E ratio of 41.73, a P/E/G ratio of 3.90 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.67 and a quick ratio of 1.94. West Pharmaceutical Services has a 12-month low of $82.74 and a 12-month high of $117.75.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Story: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.